Bokhari Raza reported grant involving 436,046 shares of Medicus Pharma Ltd. at $1.72 for $750k on Nov 13, 2026

Grant
Form 4 code A. Grant, award, or other acquisition under Rule 16b-3(d).
Chief Executive Officer
Chief Executive Officer
Filed Nov 17, 2026

Facts from the filing

Form 4 · Non-derivative, table I
Disclosed value
$749,999.12Shares × reported price
Shares traded
436,046Common Shares, no par value
Price per share
$1.72Reported price. Read footnotes for ranges.
% of reported position traded
UnavailableThis security and ownership context
Holdings after
451,909Indirect · See Footnote
Trade date
Nov 13, 2026Grant
Filed
Nov 17, 2026, 5:02 PM ET4-day reporting delay
Accession
0000950142-26-003103Code A · Transaction 404047
How reported position traded is calculated

Calculated only for code-P purchases and code-S sales.

Row-level estimate for this security and ownership context, not the insider’s complete portfolio. Joint ownership, other transactions in the filing, amendments and footnotes can affect interpretation.

Other trades in this filing

Related trades are temporarily unavailable. Open the SEC filing for the complete report, or reload this page.

MDCX price since this filing

Daily closing prices, with the filing date and available return windows. Return methodology
MDCX · Daily closing priceDaily price data is pending. The chart appears when valid daily closes are available.
Filing dateReturn windows appear as prices become available.

Return windows are pending. The first 7-day window is eligible on Nov 24, 2026. Values appear when the daily price refresh supplies a valid close for that window. Weekends, market holidays and missing prices can delay updates.

Pre-filing1mo ago 0%1w ago 0%1d ago 0%
Returns since7d30d90d180d1y

Footnotes in full

F1: On November 13, 2026, RBx Capital, LP, an entity controlled by Dr. Raza Bokhari, entered into a subscription agreement with the Issuer, pursuant to which RBx Capital, LP agreed to purchase 436,046 common shares, no par value, at a purchase price of $1.72 per share in a private placement in which other investors also participated under separate subscription agreements. F2: Held by RBx Capital, LP, an entity controlled by Dr. Raza Bokhari. The Reporting Person disclaims beneficial ownership except to the extent of his pecuniary interest therein.